Because of its involvement in signalling, it has been found to interact with other oncogenic drivers, particularly those of the RAS family, (KRAS) and so targeting SHP2 is critical for treatment of cancers associated with the different RAS oncogenes [5]. Here, PTPN11 is linked to cancer.